Delivery Order SPE2DB24D2012-SPE2DB25FBWYY
Award Date 9/16/25
Potential Completion Date 9/17/25
Potential Value $17K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a $13,431.90 delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets on April 24, 2025, with completion targeted for April 25, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $16,964.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (10-count). The contract, which is a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, has an ultimate completion date of September 11, 2025. UBRELVY is an FDA-approved acute migraine treatment...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $4,338.57 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, quantities of 16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and was competitively awarded without set-aside designation. The pharmaceutical will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $5,427.25 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packs (16 count). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 25, 2025. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for acute migraine treatment. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4,568,984,056 units of UBRELVY 100 mg tablets in unit dose packages of 16 tablets, valued at $59,129.24. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 5, 2025, and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, and this delivery order represents fulfillment...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,135.73 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10-count unit dose packages) on September 29, 2025, with completion scheduled for September 30, 2025. This competitively awarded, non-set-aside delivery order uses firm fixed pricing and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist used for acute...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 units, with a ceiling value of $18,754.48. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 10, 2025. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...